MM: Managing Toxicities From BCMA-Targeting Bispecific Antibodies
Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.
EP: 1.Recent Data in the Management of Early-Relapse Multiple Myeloma
EP: 2.Treatment Decision-Making in Early-Relapse MM
EP: 3.Multiple Myeloma Treatment: Patient Profiles
EP: 4.Recent Data on Bispecific Antibodies in Multiple Myeloma
EP: 5.Dosing Considerations for Bispecific Antibodies in MM
EP: 6.Managing Adverse Effects from Bispecific Antibodies in Multiple Myeloma
Now Viewing
EP: 7.MM: Managing Toxicities From BCMA-Targeting Bispecific Antibodies
EP: 8.Toxicities From GPRC5D-Targeting Therapies in Multiple Myeloma
EP: 9.Treatment Decision-Making in Multiple Myeloma
EP: 10.Key Takeaways on the Treatment of Patients With Relapsed/Refractory MM
EP: 11.Bispecific Antibody Dose Schedules in Relapsed/Refractory Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
